XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
Hutrukin, A Therapy Discovered and Manufactured at XBiotech, Is Aimed to Reduce Brain Injury after StrokeAUSTIN, Texas, April 17, 2023 -- XBiotech Inc. has enrolled the first subject in a... | April 17, 2023